Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Amgen and AstraZeneca win FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps Find out how Amgen and AstraZeneca’s Tezspire approval for nasal polyps redefines biologic therapy and reshapes investor confidence today. bySoujanya RaviOctober 18, 2025